Three Latham & Watkins partners in California have been named “2016 Women Leaders in Tech Law” in an annual feature published by ALM’s regional title in the state. According to The Recorder, the honored attorneys are “calm, levelheaded, persistent, determined, tenacious, strategic, bold,” and “their clients—which run the spectrum from solo entrepreneurs to tech giants—rely on them for a steady hand and sound counsel.”
Jennifer Barry is global Co-chair of Latham & Watkins’ Intellectual Property Litigation Practice and a partner in the San Diego office. She represents clients in all aspects of general commercial litigation with a particular focus on intellectual property, with specialized experience in internet law. The Recorder called out her successful representation of craigslist last year in a case which resulted in website scrapers being barred from stealing information from the online classified site, and a $3.1 million payout for the company.
Julie Holloway is a resident in the firm's San Francisco and Silicon Valley offices, and she Co-chairs the Litigation & Trial Department in San Francisco. She has extensive experience in all aspects of patent litigation through trial, and she has particular experience in cross-examining Ph.D technical experts on the complex technical issues that go to the heart of her opponent’s case. The Recorder noted her successful defense of NVIDIA in an eight-patent lawsuit brought by Samsung – called “a feat made all the more impressive by the fact that the suit played out in the Eastern District of Virginia, a notorious rocket docket.”
Judith Hasko, based in Silicon Valley and global Chair of the firm’s Life Sciences Licensing Group, regularly advises companies developing biotechnology, pharmaceutical, medical device and diagnostic products, and investors in such companies, in a wide range of technology-based commercial transactions. She was recognized for her work on enterprise-defining deals, including advising Juno Therapeutics in its $1 billion collaboration with Celgene, which involved the highest ever upfront payment for a biopharma licensing deal.